论文部分内容阅读
本文研究了在七名正常人及七名肝硬化伴腹水病人口服40mg速尿后的动力学和药效学性质,由于病人组肾功能的衰退,其t_(1/2)有延长(1.22±0.43hr及1.44±0.46hr)及总清除率有降低(13.52±3.39l/hr及10.6±5.1 l/hr)的趋向。二组间对速尿的吸收差异显著,病人组对速尿吸收滞后时间的发生率降低,吸收速率常数仅为正常组的30%,大多数受试者的排尿速率与血药浓度的对数间有相关关系,但有些病人却没有。病人组与正常组在11小时内尿中速尿的回收率分别为38.1±24.5%及48.3±20%;两组11小时内累积尿量为24小时内的比较百分率分别为62.3±15.6%及85±8.7%。药效学参数病人组为m=2908±744、e=858±40,而正常组为m=2973±887、e=971±50.5,其间没有差异。
This study investigated the kinetic and pharmacodynamic properties of seven normal people and seven cirrhotic patients with ascites after oral administration of 40 mg of furosemide. Due to the decline of renal function, the t 1/2 (1.22 ± 0.43 hr and 1.44 ± 0.46 hr) and total clearance (13.52 ± 3.39 l / hr and 10.6 ± 5.1 l / hr), respectively. There was significant difference between the two groups in the absorption of furosemide, and the incidence of furosemide in the patient group was decreased, the absorption rate constant was only 30% of that in the normal group, and the logarithm of urinary excretion rate and plasma concentration in most of the subjects There is a correlation, but some patients do not. The recovery rate of urinary furosemide in patients and normal group was 38.1 ± 24.5% and 48.3 ± 20% respectively in 11 hours. The accumulative urine output within 11 hours in both groups was 62.3 ± 15.6% in 24 hours and 85 ± 8.7%. The pharmacodynamic parameters were m = 2908 ± 744 and e = 858 ± 40 in the patient group, and m = 2973 ± 887 and e = 971 ± 50.5 in the normal group, respectively. There were no differences between the two groups.